v3.25.2
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jan. 01, 2025
Sep. 30, 2024
USD ($)
Dec. 31, 2022
USD ($)
Number of Tumor Samples 150,000        
Number of Operating Segments 2        
Retained Earnings (Accumulated Deficit) $ (180,426,271) $ (167,761,883)      
Cash and Cash Equivalents, at Carrying Value 611,822 8,357,294      
Liabilities, Current 3,593,401 3,951,031      
Operating Lease, Liability, Current 1,558,239 2,113,408      
Net Cash Provided by (Used in) Operating Activities (10,103,084) (10,766,475)      
Equity, Attributable to Parent (202,610) 8,271,780   $ 1,966,969 $ 21,765,892
Research and Development Expense, Total 20,728 $ 98,114      
Unrecognized Tax Benefits $ 0        
Renovaro Acquisition [Member] | Renovaro Preferred Stock [Member]          
Business Acquisition, Equity Interest Issued and Issuable, Exchange Rate     1